Reboxetine: review of benefits and risks

14 September 2011

Reboxetine (brand name Edronax) is used to treat depression.

A European review of data has shown that reboxetine is an effective medicine for severe clinical depression, and that the balance of its benefits and risks remains positive.

A summary of the data reviewed is presented in this Public Assessment Report.

This report presents the evidence that was available when the regulatory decision was made, showing a ‘snapshot’ of the clinical landscape at the time. However, any advice in this report remains current unless it is superseded by a more recent report (where relevant, this is indicated).

Page last modified: 11 February 2016